Muzolimine therapy in patients with congestive heart failure in comparison with furosemide pretreatment. Effect on digoxin plasma concentration.
Eight patients suffering from congestive heart failure (NYHA III-IV) and pretreated with digoxin received muzolimine over 14 days in an open clinical study. The muzolimine dose was adjusted to 3/4 of the daily furosemide dose necessary to keep the body weight constant at least three days prior to the onset of muzolimine treatment. Plasma concentrations of epinephrine, norepinephrine, aldosterone, renin and digoxin were determined on the last day of the furosemide treatment period and on the last day of the muzolimine period. No significant changes were observed in plasma concentrations of epinephrine, aldosterone, renin, creatinine, and potassium. After muzolimine treatment, however, body weight and sonographically determined liver size decreased further and plasma norepinephrine concentrations were significantly lower. The digoxin concentrations did not change after muzolimine treatment. The results demonstrate the beneficial effect of muzolimine in heart failure patients. Since plasma concentration of digoxin does not change despite marked diuretic effects of muzolimine no relevant interaction between both substances has to be expected.
D000328:Adult; D000368:Aged; D004077:Digoxin / Q000097:blood* / Q000627:therapeutic use; D004347:Drug Interactions; D004837:Epinephrine / Q000097:blood; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009156:Muzolimine / Q000627:therapeutic use*; D009638:Norepinephrine / Q000097:blood; D009994:Osmolar Concentration; D011720:Pyrazoles / Q000627:therapeutic use*
D011720:Pyrazoles; D009156:Muzolimine; D004077:Digoxin; D005665:Furosemide; D009638:Norepinephrine; D004837:Epinephrine